Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28531937 | 0.79 | ALDH1A1 (0.42) | NPSR1ALDH1A1TSHRFDPSMAPT | |
| SCHEMBL15435175 | 0.72 | LMNA (0.41) | ALDH1A1TSHRFDPSKDM4EPTGS2 | |
| SCHEMBL23654320 | 0.69 | IDH1 (0.34) | ALDH1A1TSHRFDPSMAPTKDM4E | |
| SCHEMBL15322610 | 0.69 | RAB9A (0.35) | ALDH1A1TSHRFDPSKDM4EPTGS2 | |
| SCHEMBL14806542 | 0.69 | DDB1 (0.45) | RAB9A | |
| SCHEMBL29576635 | 0.69 | — | — | |
| SCHEMBL305358 | 0.69 | — | — | |
| SCHEMBL29387096 | 0.68 | CCR1 (0.42) | ALDH1A1TSHRFDPSKDM4EPTGS2 | |
| SCHEMBL730405 | 0.68 | CCR1 (0.42) | ALDH1A1TSHRFDPSKDM4EPTGS2 | |
| Hydrochloric Acid SCHEMBL29955353 | 0.67 | UHRF1 (0.48) | ALDH1A1TSHRFDPSKDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | NPSR1 1625/4885ALDH1A1 114/4885TSHR 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.